CHEMOTHERAPY AND IMMUNOTHERAPY FOR DISSEM INATED MALIGNANT MELANOMAS

Prognosis in metastatic malignant melanoma is poor because of chemo an d radiotherapy resistance, However, some drugs, such as dacarbazine, c isplatinum or fotemustine, a new nitrosourea, have produced a response rate of more than 20%, Combining these drugs increases response rate to 30-40%, Immunotherapy by interferon-alpha2 shows about 15-20% respo nse rate but interleukin-2 would be more effective especially in combi nation with cisplatinum and interferon-alpha2 with 50% resone and long survival after cessation of treatment.